华仁药业(300110.SZ)：安徽恒星制药的盐酸异丙肾上腺素原料药获得上市申请批准通知书

Core Viewpoint - Huaren Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the marketing application of Isoproterenol Hydrochloride, indicating a significant advancement in its product portfolio and potential market opportunities [1] Group 1: Company Developments - Huaren Pharmaceutical's wholly-owned subsidiary, Anhui Hengxing Pharmaceutical Co., Ltd., has been granted the approval for Isoproterenol Hydrochloride, a non-selective β-adrenergic agonist [1] - The approval notification number for the marketing application is 2025YS00767, highlighting the regulatory progress made by the company [1] Group 2: Product Information - Isoproterenol Hydrochloride is known for its strong positive inotropic and chronotropic effects, as well as its bronchodilator properties, making it clinically relevant for treating conditions such as cardiogenic or septic shock, complete atrioventricular block, cardiac arrest, and acute bronchial asthma attacks [1]